EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

This clinical trial will evaluate the safety and efficacy of \[161Tb\]Tb -PSMA-I\&T in men with metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT05521412
Phase
PHASE1 / PHASE2
Sponsor
Peter MacCallum Cancer Centre, Australia
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • [ 161 Tb]Tb PSMA I&T
Locations (sample)
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Patient has provided written informed consent.
  • Male patients must be 18 years of age or older at the time of written informed consent.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate, OR unequivocal diagnosis of metastatic prostate cancer (i.e., involving b…
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →